Here are the 424B prospectus supplements from Vor Biopharma Inc. (VOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. (VOR) entered into a sales agreement with William Blair & Company, L.L.C. and RBC Capital Markets, LLC to offer and sell common stock from time to time at an aggregate offering price of up to $150,000,000. Sales may be made through at-the-market offerings or negotiated transactions, including block trades; the agents are not required to sell a specific amount. Their commission is up to 3.0% of gross sales.
Vor intends to use net proceeds for working capital, capital expenditures and general corporate purposes, with possible investment in or acquisition of complementary businesses or technologies. An illustrative scenario assumes a sale of 7,173,601 shares at $20.91 per share and shows immediate dilution of $20.79 per share to purchasers. The prior sales agreement expired after $125 million of common stock sales, and no further shares may be sold under it.
Vor’s global Phase 3 trial of telitacicept for generalized myasthenia gravis completed enrollment in September 2026, with topline data anticipated in the first half of 2027. The company plans a global Phase 3 trial in ocular myasthenia gravis, with enrollment anticipated to begin in the first half of 2027.
Vor Biopharma Inc. has filed a resale prospectus covering up to 13,876,032 shares of common stock previously issued in a December 18, 2025 private placement. These shares were sold to accredited investors at $10.81 per share for gross proceeds of $150 million.
The company is a clinical-stage biopharmaceutical business developing telitacicept for autoimmune diseases, including a global Phase 3 trial in generalized myasthenia gravis. Only the selling stockholders will receive proceeds from any share sales; Vor will cover registration costs but not selling expenses. The filing warns that large resales could pressure the stock price and notes that prior audited financial statements included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.